Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Renal Drug Clearance: Overview01:06

Renal Drug Clearance: Overview

405
Renal clearance is a crucial parameter in pharmacokinetics that quantifies the rate at which the kidneys excrete a drug. It represents a constant fraction of the central volume of distribution containing the drug that the kidney eliminates per unit of time.
Renal clearance can be calculated using different methods. One approach is to divide the urinary drug excretion rate by the plasma drug concentration. This method directly measures renal clearance, indicating the kidneys' efficiency in...
405
Renal Drug Excretion: Overview01:15

Renal Drug Excretion: Overview

369
As primary excretory organs, the kidneys maintain homeostasis by removing waste substances from the bloodstream. They comprise over a million units called nephrons, which serve as the kidney's functional units.
A nephron consists of two primary structures: the renal corpuscle and the renal tubule. The renal corpuscle contains the glomerulus, a network of capillaries where the first step of renal excretion, glomerular filtration, occurs. Blood pressure forces water, ions, and small molecules...
369
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

925
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
925
Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

196
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
196
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

581
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
581
Renal Clearance01:23

Renal Clearance

1.6K
The glomerular filtration rate (GFR) is a critical marker of kidney function, reflecting the efficiency of filtration by the glomeruli. Renal clearance of specific substances, such as inulin or creatinine, is commonly used to measure GFR.
Renal clearance refers to the volume of plasma cleared of a specific substance, such as creatinine, per unit of time. To measure clearance, urine samples are collected over a 24-hour period during each bladder voiding, followed by a single blood sample at the...
1.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction: Ivosidenib: A Review in Advanced Cholangiocarcinoma.

Targeted oncology·2024
Same author

Pemigatinib: A Review in Advanced Cholangiocarcinoma.

Targeted oncology·2024
Same author

Ivosidenib: A Review in Advanced Cholangiocarcinoma.

Targeted oncology·2023
Same author

Epcoritamab: First Approval.

Drugs·2023
Same author

Correction to: Fenfluramine: A Review in Dravet and Lennox-Gastaut Syndromes.

Drugs·2023
Same author

Fenfluramine: A Review in Dravet and Lennox-Gastaut Syndromes.

Drugs·2023

Related Experiment Video

Updated: Oct 20, 2025

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

3.6K

Finerenone: First Approval.

James E Frampton1

  • 1Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. dru@adis.com.

Drugs
|September 14, 2021
PubMed
Summary
This summary is machine-generated.

Finerenone is a new drug approved to protect adults with type 2 diabetes and chronic kidney disease from serious kidney and heart problems. This selective mineralocorticoid receptor antagonist offers a novel treatment approach for these high-risk patients.

More Related Videos

Optimization of the Epimedii Folium Mutton-Oil Processing Technology and Testing Its Effect on Zebrafish Embryonic Development
06:00

Optimization of the Epimedii Folium Mutton-Oil Processing Technology and Testing Its Effect on Zebrafish Embryonic Development

Published on: March 17, 2023

618
Hydrodynamic Renal Pelvis Injection for Non-viral Expression of Proteins in the Kidney
08:26

Hydrodynamic Renal Pelvis Injection for Non-viral Expression of Proteins in the Kidney

Published on: January 8, 2018

19.0K

Related Experiment Videos

Last Updated: Oct 20, 2025

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

3.6K
Optimization of the Epimedii Folium Mutton-Oil Processing Technology and Testing Its Effect on Zebrafish Embryonic Development
06:00

Optimization of the Epimedii Folium Mutton-Oil Processing Technology and Testing Its Effect on Zebrafish Embryonic Development

Published on: March 17, 2023

618
Hydrodynamic Renal Pelvis Injection for Non-viral Expression of Proteins in the Kidney
08:26

Hydrodynamic Renal Pelvis Injection for Non-viral Expression of Proteins in the Kidney

Published on: January 8, 2018

19.0K

Area of Science:

  • Nephrology
  • Cardiology
  • Endocrinology

Background:

  • Diabetic kidney disease (DKD) and heart failure (HF) are significant complications of type 2 diabetes (T2D).
  • Current treatments for DKD and HF in T2D patients have limitations in preventing disease progression and cardiovascular events.
  • Mineralocorticoid receptor antagonists (MRAs) play a role in managing fluid balance and fibrosis, but non-selective MRAs have risks.

Purpose of the Study:

  • To summarize the development milestones of finerenone, a selective nonsteroidal MRA.
  • To highlight the regulatory approval of finerenone for reducing kidney and heart complications in adults with CKD and T2D.

Main Methods:

  • Review of clinical trial data and regulatory submissions for finerenone.
  • Analysis of finerenone's pharmacological profile as a selective MRA.

Main Results:

  • Finerenone demonstrated efficacy in reducing the risk of sustained estimated glomerular filtration rate (eGFR) decline, end-stage renal disease (ESRD), cardiovascular death, nonfatal myocardial infarction (MI), and HF hospitalization.
  • The drug has received approval in the USA for these indications and is under regulatory review in the EU and China.

Conclusions:

  • Finerenone represents a first-in-class, orally administered, selective MRA for the treatment of DKD and HF in patients with T2D.
  • Its approval marks a significant advancement in managing cardiorenal complications associated with T2D.